After the release of the policy of "Hong Kong Macao medical equipment link", which allows patients in Guangdong, Hong Kong and Macao to use drugs and medical devices that have been approved in Hong Kong but have not been registered in the mainland, there has been a lot of progress in relevant fields recently - last month, Guangdong Provincial Drug Administration and Guangdong Health Commission issued the second batch of catalogue of drugs and medical devices urgently needed to be imported from Hong Kong and Macao in the mainland of Guangdong, Hong Kong and Macao, and decided to add six drugs; On March 2, Zhongshan chenxinghai hospital, Hong Kong comprehensive tumor center, a leading cancer treatment center in Hong Kong, and medical logistics distributor Dachang aolijia announced that they had reached a strategic cooperation on medical services in Dawan district with the theme of "medical equipment, linkage and sharing", so as to support the implementation of the "Hong Kong Macao medical equipment link" policy. It is understood that the policy of "Hong Kong and Macao medical equipment link" allows drugs and medical devices that have been listed in Hong Kong and Macao, widely used in public hospitals, and are in urgent clinical need or needed in the mainland to be imported through pilot medical institutions. In August last year, the pilot hospitals were expanded to five, namely Guangzhou united family hospital, Guangzhou modern hospital, Zhongshan Chen Xinghai hospital Zhuhai ximalin Shunchao ophthalmic hospital and Shenzhen Hospital of the University of Hong Kong. The cooperation plans to introduce 10 newly approved treatment methods for pilot hospitals during the year In February this year, the second batch of catalogue of "Hong Kong Macao pharmaceutical machinery communication" was announced. Zhongshan chenxinghai hospital also received the first batch of anti-cancer new drugs "loratinib" and "ntratinib" in February this year. Under this policy, doctors in Tai Wan district can formulate treatment methods for local patients with urgent needs in Hong Kong public hospitals according to individual cases. In addition to providing new nursing options, case reports can be used as a reference for clinical trials, so as to help promote the registration and adoption of relevant treatment methods in the mainland. There are about 200 kinds of treatment methods that meet the requirements of the plan, and nearly 25 kinds of drugs and medical devices have been approved by Guangdong Drug Administration and Guangdong Health Commission, including cutting-edge cancer treatment methods. At present, Zhongshan chenxinghai hospital has successfully introduced two international new oral anticancer drugs. The goal of this cooperation is to introduce 10 newly approved treatment methods for the hospital in 2022. Dr. Huang Zhihao, executive director of Zhongshan chenxinghai hospital group, said that he would actively cooperate with strategic partners to build a comprehensive support network for patients, so as to provide new treatment methods as soon as possible. Tripartite cooperation helps build the logistics network of "Hong Kong Macao pharmaceutical machinery link" As a special commodity, the logistics and distribution requirements of drugs are very strict. With the support of the policy of "Hong Kong Macao pharmaceutical machinery link", how to safely and quickly transport drugs to hospitals is another practical problem. In this regard, Richard Holloway, vice president of medical care in mainland China, Hong Kong and Macao, said that at present, the company has distributed "cabotinib", "aminohexenoic acid", "erdatinib" and "loratinib" and other drugs in Dawan District, and strictly controlled the cold chain transportation process of drugs. He said that Hong Kong's own advantages in the transportation industry can effectively improve the transportation efficiency of pharmaceutical products, while the enterprise has accumulated rich experience in managing the medical supply chain, medical public welfare projects and medical product registration. These advantages can be used to promote information sharing, approval procedures and logistics supply chain. Just last month, Dachang aolijia also launched a medical interactive platform, Dawan huiyi.com, through which the medical community can learn about the "Hong Kong Macao pharmaceutical and mechanical communication" policy and more clinical information about the review of newly approved treatment methods. On the one hand, Dachang aolijia will provide logistics support for medical instruments. On the other hand, Hong Kong comprehensive tumor center will provide remote services for patients in Zhongshan chenxinghai hospital through cross specialist remote video consultation system. Tang Jiaqi, chief executive of the Hong Kong comprehensive cancer center, said that the center and Zhongshan Chen Xinghai hospital have provided medical services for patients in the mainland through the system and promoted medical service cooperation in Dawan district. In addition to helping to complement the medical advantages in the region, this model is also conducive to meeting the actual needs of patients. (Xinhua News Agency)